Executive Summary
China’s equity markets are set to welcome a significant milestone with the arrival of the first batch of newly registered Sci-Tech Innovation Board Growth Layer stocks. These listings represent a pivotal moment for investors seeking exposure to high-growth, innovative sectors within China’s evolving capital markets framework.
- HeYuan Bio, Xi’an YiCai, and BiBeiTe are the inaugural companies, all currently unprofitable but positioned for potential growth under specialized regulatory provisions.
- Differentiated lock-up and allocation mechanisms are being implemented to stabilize pricing and attract long-term institutional capital.
- Over 335,000 investors participated in initial subscriptions, with 5 million already granted trading permissions for the Growth Layer, indicating robust market interest.
- These newly registered Sci-Tech Innovation Board Growth Layer stocks introduce unique risk-reward profiles, requiring investors to sign additional disclosures before trading.
- The listings underscore China’s commitment to fostering innovation through tailored market segments, offering new avenues for global portfolio diversification.
A New Era in Chinese Equity Markets
The debut of the first newly registered Sci-Tech Innovation Board Growth Layer stocks marks a transformative phase in China’s financial landscape. As global investors increasingly focus on Asian markets, this development provides unprecedented access to cutting-edge companies in biotechnology and semiconductors. The Sci-Tech Innovation Board (科创板) continues to evolve, with the Growth Layer (科创成长层) specifically designed to accommodate firms in early growth stages, even if they are not yet profitable.
This initiative aligns with broader economic strategies to bolster technological self-reliance and innovation-driven growth. For institutional investors, the newly registered Sci-Tech Innovation Board Growth Layer stocks represent a calibrated opportunity to engage with China’s next-generation industries. The regulatory framework ensures that while risks are higher, the potential rewards could be substantial, supported by robust disclosure requirements and investor protections.
Understanding the Growth Layer Framework
The Sci-Tech Innovation Board Growth Layer was established to host companies that are in the growth phase but may not have achieved profitability. According to the Shanghai Stock Exchange (SSE) guidelines, firms listed under this category must demonstrate significant innovation potential and growth prospects. The newly registered Sci-Tech Innovation Board Growth Layer stocks are subject to specific rules outlined in the SSE’s Self-Regulatory Guidance, which mandates enhanced disclosures and risk management practices.
Unprofitable companies are included from their listing date, provided they meet the criteria. This approach allows investors to participate in early-stage growth while maintaining transparency. The SSE has implemented labeling systems, such as U for unprofitable status and tags like 成 for new registrations, to help investors easily identify and assess these securities. This structured environment aims to balance innovation facilitation with market stability.
Inaugural Companies and Their Profiles
The first batch of newly registered Sci-Tech Innovation Board Growth Layer stocks features three prominent firms: HeYuan Bio (禾元生物), Xi’an YiCai (西安奕材), and BiBeiTe (必贝特). Each company operates in high-innovation sectors, reflecting China’s strategic priorities in healthcare and technology. Despite their current unprofitability, they have secured listings based on robust pipelines and market potential.
HeYuan Bio, a biotechnology firm, pioneered the use of the fifth set of listing standards on the Sci-Tech Innovation Board after its reopening. The company has eight drug pipelines in development, with its recombinant human albumin injection (OsrHSA, HY1001) approved for cirrhosis-related hypoalbuminemia in July 2025. Xi’an YiCai, a leader in 12-inch silicon wafers, ranks first in China and sixth globally by capacity and shipment volume. BiBeiTe focuses on innovative drugs, with one product already approved and others in advanced clinical trials.
Financial Performance and Market Positioning
As of their prospectus disclosures, all three companies reported losses. In the first half of 2025, HeYuan Bio recorded a net loss of 81.6278 million yuan, BiBeiTe 73.8929 million yuan, and Xi’an YiCai 340 million yuan. These figures highlight the high-risk, high-reward nature of the newly registered Sci-Tech Innovation Board Growth Layer stocks. Investors are betting on future profitability driven by product commercialization and market expansion.
The companies adopted different listing standards: HeYuan Bio and BiBeiTe used the fifth set, while Xi’an YiCai utilized the fourth set, emphasizing their distinct operational focuses. This diversity underscores the flexibility of the Sci-Tech Innovation Board in accommodating varied business models. For global investors, these profiles offer a glimpse into sectors poised for growth, albeit with inherent volatility.
Differentiated Lock-up and Allocation Mechanisms
A key innovation in this batch is the implementation of differentiated lock-up and allocation arrangements for net issuance. The Shanghai Stock Exchange revised underwriting rules earlier this year to allow unprofitable companies to adopt customized lock-up periods. This approach encourages net investors to commit to longer holding periods in exchange for higher allocation quotas, promoting price stability and reducing speculative trading.
For HeYuan Bio, the net lock-up ratio is at least 40%, with three tiers: 70% lock-up for 9 months, 45% for 6 months, and 10% for 6 months. Xi’an YiCai and BiBeiTe have similar structures, with lock-up ratios ranging from 20% to 60% over 6 to 9 months. These mechanisms are designed to attract investors who can conduct thorough due diligence and maintain long-term positions, aligning with the strategic goals of the newly registered Sci-Tech Innovation Board Growth Layer stocks.
Impact on Pricing and Market Dynamics
The tiered lock-up system directly influences subscription behavior and pricing efficiency. In HeYuan Bio’s case, investors opting for the highest lock-up tier received allocation ratios up to nine times higher than those in the lowest tier. This incentivizes professional institutions to submit more accurate valuations, reducing the likelihood of overpricing. For the newly registered Sci-Tech Innovation Board Growth Layer stocks, this model aims to foster a more mature market environment where pricing reflects fundamental value rather than short-term speculation.
Data from initial subscriptions shows strong institutional participation, with net investors demonstrating confidence in the long-term prospects of these companies. This trend is expected to continue as more newly registered Sci-Tech Innovation Board Growth Layer stocks enter the market, potentially setting a precedent for future listings. Investors should monitor allocation patterns to gauge market sentiment and liquidity conditions.
Investor Participation and Accessibility
Retail and institutional interest in the newly registered Sci-Tech Innovation Board Growth Layer stocks has been remarkable. HeYuan Bio’s online subscription attracted over 335,9036 valid applications, with an initial win rate of approximately 0.036%. After mechanisms were activated, the final online win rate adjusted to 0.054%, indicating high demand. This surge in participation underscores the appeal of these innovative investment vehicles.
To trade these securities, investors must sign the Sci-Tech Innovation Board Stock Investor Risk Disclosure Document and the additional Growth Layer Risk Disclosure Document. As of September 22, 5 million investors had already completed the necessary procedures through their brokerage apps. The streamlined permission process, coupled with educational labels like U and 成, ensures that participants are adequately informed about the risks and opportunities associated with the newly registered Sci-Tech Innovation Board Growth Layer stocks.
Subscription Details and Market Response
HeYuan Bio set its issue price at 9.45 yuan, with an online subscription cap of 12,500 shares requiring a market value of 125,000 yuan for full subscription. Xi’an YiCai priced at 8.62 yuan, with a cap of 53,500 shares and a corresponding market value of 535,000 yuan. BiBeiTe’s subscription cap is 14,000 shares, needing 140,000 yuan in market value. These thresholds are designed to balance accessibility with prudent risk management.
The high subscription multiples, such as HeYuan Bio’s 2767.09 times pre-recall, reflect intense market interest. This enthusiasm is partly driven by the unique attributes of the newly registered Sci-Tech Innovation Board Growth Layer stocks, which offer exposure to sectors with significant growth tailwinds. Investors should consider these dynamics when evaluating allocation strategies and portfolio diversification.
Regulatory Environment and Future Outlook
The introduction of the newly registered Sci-Tech Innovation Board Growth Layer stocks is underpinned by comprehensive regulatory frameworks. The Shanghai Stock Exchange’s Self-Regulatory Guidance No. 5 outlines specific requirements for disclosure, corporate governance, and investor communication. These rules ensure that while companies may be unprofitable, they maintain high standards of transparency and accountability.
Looking ahead, the success of these initial listings could pave the way for more companies to join the Growth Layer. Regulatory authorities are likely to refine policies based on market feedback, potentially expanding eligibility criteria or adjusting lock-up mechanisms. For investors, this evolving landscape offers a dynamic investment arena, but requires continuous monitoring of regulatory updates and market trends.
Expert Insights and Strategic Recommendations
Industry analysts emphasize that the newly registered Sci-Tech Innovation Board Growth Layer stocks represent a strategic allocation for investors with higher risk tolerance. David Zhang, a senior analyst at CICC (中国国际金融有限公司), notes, These listings are not just about immediate returns; they are bets on China’s technological future. Investors should focus on companies with clear paths to commercialization and strong intellectual property portfolios.
Portfolio managers recommend a balanced approach, combining these high-growth stocks with more stable assets to mitigate volatility. The differentiated lock-up periods provide an additional layer of security, as they align investor interests with long-term company performance. As the market for newly registered Sci-Tech Innovation Board Growth Layer stocks matures, we may see increased institutional participation and more sophisticated valuation models emerge.
Key Takeaways and Next Steps for Investors
The debut of the newly registered Sci-Tech Innovation Board Growth Layer stocks is a landmark event for China’s capital markets. These listings offer unique opportunities to invest in innovative sectors, supported by tailored regulatory frameworks and robust investor protections. However, the unprofitable nature of these companies necessitates careful risk assessment and due diligence.
Investors should proactively review their brokerage permissions and ensure they have signed the required risk disclosure documents. Monitoring subscription data, lock-up arrangements, and company-specific developments will be crucial for making informed decisions. As the market evolves, staying updated on regulatory changes and sector trends will enable investors to capitalize on the growth potential of the newly registered Sci-Tech Innovation Board Growth Layer stocks while managing associated risks effectively.